Corteva cut 2026 operating EBITDA outlook to $1.1 to $1.125 billion from about $1.3 billion due to worsening Brazil conditions. Third-quarter net sales were $1.6 billion, down 9%, and operating EBITDA was $222 million, down 17%.
CTVA · Corteva, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Corteva completed the separation of its Seed Business into independent publicly traded Vylor through a pro rata dividend in-kind on October 1, 2026, leaving New Corteva as the Crop Protection Business.
Corteva completed its Seed separation on October 1, 2026, creating Vylor Inc. Third-quarter net sales fell 6% to $2,458 million and operating EBITDA turned negative at $(68) million, while nine-month sales rose 2% to $13,742 million.
Corteva reported third-quarter net sales of $1.59B, down 9%, as Brazil market conditions weakened. Full-year Adjusted Pro Forma Operating EBITDA guidance was lowered to between $1.1 billion and $1.125 billion.
Corteva and EIDP delayed their September 30, 2026 quarterly report after the October 1, 2026 seed-segment spin-off. They expect a higher seasonal loss than in 2025 and plan to issue results before the November 12, 2026 earnings call.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 12, 2026TL;DR. New-product growth, regional organic growth outside Latin America, productivity and year-to-date margin expansion supported the business. However, Brazil-driven weakness caused a sharp third-quarter decline, reduced full-year EBITDA guidance and implied fourth-quarter EBITDA of about half of 2025 levels.
- + New product volumes grew 20% in the quarter, with growth in every region.
- + North America, EMEA and Asia Pacific delivered organic growth in the quarter.
- + Year-to-date operating EBITDA was essentially flat and margins expanded 30 basis points despite more than approximately $230 million of pricing headwinds.
- + Cost-of-goods productivity and lower SG&A spending more than covered increased R&D investment, producing a $67 million quarterly benefit.
- + The board declared Corteva’s first quarterly dividend as a standalone company.
- + Corteva remained on track for a targeted year-end cash position of roughly $1.5 billion.
- − Third-quarter net sales fell 9%, operating EBITDA fell 17% and operating EBITDA margin contracted 140 basis points.
- − Latin America organic sales declined 31% in the third quarter.
- − Latin American volume decreased 24% due to elevated channel inventory and delayed purchasing, while price declined 7% amid competitive pressure on mature molecules.
- − Full-year operating EBITDA guidance was reduced from about $1.3 billion to $1.1 billion–$1.125 billion.
- − Fourth-quarter operating EBITDA is expected to be about half of 2025 levels because of Brazil’s significance to fourth-quarter results.
- − Elevated Brazil channel inventory is expected to create an approximately $100 million full-year EBITDA impact.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Pro Forma Base Income Tax Rate From Continuing Operations (Non-GAAP) non-GAAP | 14.7% | Nine Months Ended September 30 | — |
| Adjusted Pro Forma Operating Earnings (Loss) (Non-GAAP) non-GAAP | $513M | Nine Months Ended September 30 | — |
| Adjusted Pro Forma Operating Earnings (Loss) Per Share (Non-GAAP) non-GAAP | $0.76 | Nine Months Ended September 30 | — |
| Adjusted Pro Forma Operating EBITDA (Non-GAAP) non-GAAP | $943M | Nine Months Ended September 30 | — |
| Adjusted Pro Forma Operating EBITDA margin non-GAAP | 17.6% | YTD 2026 | — |
| Asia Pacific organic sales growth non-GAAP | 5% | third quarter of 2026 | — |
| Asia Pacific price growth | -2% | third quarter of 2026 | — |
| Asia Pacific volume growth | 7% | third quarter of 2026 | — |
| EMEA organic sales growth non-GAAP | 14% | third quarter of 2026 | — |
| Latin America organic sales growth non-GAAP | -31% | third quarter of 2026 | — |
| Latin America price growth | -7% | third quarter of 2026 | — |
| Latin America volume growth | -24% | third quarter of 2026 | — |
| North America organic sales growth non-GAAP | 7% | third quarter of 2026 | — |
| North America volume growth | 19% | third quarter of 2026 | — |
| Operating EBITDA non-GAAP | $943M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Organic Change 1(Non-GAAP) non-GAAP | -9% | Q3 2026 vs. Q3 2025 | — |
| Pro Forma Operating Earnings (Loss) (Non-GAAP) non-GAAP | $528M | Nine Months Ended September 30 | — |
| Pro Forma Operating EBITDA (Non-GAAP) non-GAAP | $960M | Nine Months Ended September 30, 2026 | — |
| Pro Forma Organic Sales (Non-GAAP) non-GAAP | $5.2B | Nine Months Ended September 30, 2026 | — |
| Average Price Paid per Share | $80.77 | the three months ended June 30, 2026 filing | — |
| Segment operating EBITDA - Total | $2.31B | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Income (loss) from continuing operations after income taxes 1.22B
+408M Provision for (benefit from) income taxes on continuing operations
+339M Depreciation and amortization
-27M Interest income
+47M Interest expense
+75M Exchange (gains) losses - net
+17M Non-operating (benefits) costs - net
+21M Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges
+85M Significant items (benefit) charge
+79M Separation costs
+47M Corporate expenses
= Segment operating EBITDA - Total 2.31B
|
|||
| Shares repurchased and retired under 2024 Share Buyback Plan | 3,095,000 | the three months ended June 30, 2026 filing | — |
| Total cost of shares repurchased under 2024 Share Buyback Plan (excluding excise taxes) | $250M | the three months ended June 30, 2026 filing | — |
| Total Number of Shares Purchased | 3,095,201 | the three months ended June 30, 2026 filing | — |
| Base income tax rate from continuing operations (Non-GAAP) non-GAAP | 20.1% | Six Months Ended June 30 | — |
| Diluted Shares | 671.6M | Six Months Ended June 30 | — |
| Operating Earnings (Loss) (Non-GAAP) non-GAAP | $2.55B | Six Months Ended June 30 | — |
| Operating EPS non-GAAP | $3.8 | 1H 2026 | — |
| Segment operating EBITDA - Crop Protection non-GAAP | $776M | 1H 2026 | — |
| Segment operating EBITDA - Seed non-GAAP | $3B | 1H 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Agricultural Inputs — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTVA
this stock
Corteva, Inc.
|
$6.29B | -85.9% | +2.9% | 8.2 | 7.6% |
|
NTR
Nutrien Ltd.
|
$33.78B | +15.4% | — | — | 1.8% |
|
CF
CF Industries Holdings, Inc.
|
$18.30B | +61.7% | +19.3% | 8.9 | 6.1% |
|
YARIY
Yara International ASA
|
$10.87B | +4.7% | — | — | 0.0% |
|
MOS
Mosaic Co
|
$6.97B | -9.0% | +8.4% | — | 11.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 41
Corteva completed the separation of its Seed Business into independent publicly traded Vylor through a pro rata dividend in-kind on October 1, 2026, leaving New Corteva as the Crop Protection Business.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTVA | -20.8% | -26.8% | -88.1% | -19.0% | -85.9% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -23.4% | -25.6% | -88.6% | -18.8% | -96.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.